STAT+: Inhibrx claims first win for long-sought immunotherapy target

Data ReadoutpositivePositive

AI Analysis

Summary

Inhibrx announced a positive result for a drug candidate targeting a long-sought immunotherapy target. The achievement represents a significant milestone for the company in a historically challenging therapeutic area.

Outcome Details

Inhibrx claims first win for long-sought immunotherapy target

Importance:5/10

Sentiment:

0.60

immunotherapyclinical trialdrug development

Related Companies

$CBDY $TRAX

Read the original article

Published by STAT News on September 8, 2026 11:30 AM

Read Original